NovaScreen Receives Wyeth Contract for High Throughput Screen
Advertisement
NovaScreen Biosciences Corporation, a Caliper Life Sciences Company, announced that Wyeth Pharmaceuticals, a division of Wyeth, has selected NovaScreen to conduct a high-throughput screening (HTS) campaign. As a result, NovaScreen will screen 500,000 compounds against an inflammatory target.
The HTS campaign combines NovaScreen's kinase profiling expertise with Caliper's LabChip(R) 3000 microfluidic screening platform, which utilizes electrophoretic separation of assay components to provide analytical quality data that is highly reproducible.